IL-6 and soluble IL-6 receptors (sIL-6R and sgp130) in human pleural effusions: massive IL-6 production independently of underlying diseases

Doré, P.; Lelièvre, Éric; Morel, Franck; Brizard, A.; Fourcin, Maryvonne; Clément, Claude; Ingrand, P.; Daneski, L.; Gascan, Hugues; Wijdenes, John; Gombert, Jean‐Marc; Preud’homme, Jean-Louis; Lecron, Jean‐Claude

doi:10.1046/j.1365-2249.1997.d01-889.x

Cited by 19 publications

(13 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, the data obtained from different individual showed only a modest change, especially in CD, indicating that circulating levels of sgp130 should be evaluated individually in each patient. The measurement of serum sgp130 probably does not have a role in specific diagnosis because it is likely to be raised in other disease conditions [27]. Nevertheless, its serial measurement may help to determine disease prognosis and confirm treatment efficacy.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A form of circulating interleukin-6 receptor component soluble gp130 as a potential interleukin-6 inhibitor in inflammatory bowel disease

Mitsuyama

Tomiyasu

Suzuki

et al. 2005

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SummaryThe presence and the role of soluble gp130, the soluble form of a component of the interleukin (IL)-6 receptor complex, were investigated in inflammatory bowel disease. The serum concentrations of soluble gp130 were increased in ulcerative colitis (active disease, median, 93·5 ng/ml; interquartile range, 26-125 ng/ml; inactive disease, 81 ng/ml, 24·8-137·3 ng/ml) and to a lesser extent in Crohn's disease (active disease, 66 ng/ml, 44·4-87·6 ng/ml; inactive disease, 63 ng/ml, 43·5-82·5 ng/ml) compared to normal controls (43 ng/ml, 27-59 ng/ml). Paired analysis of serum samples showed a decrease of IL-6 and soluble IL-6 receptor concentrations in both diseases and an increase of soluble gp130 concentrations, especially in ulcerative colitis, just after the resolution of disease exacerbation. Size fractionation of the serum revealed that a part of the IL-6 co-eluted with soluble gp130 and soluble IL-6 receptor. The IL-6-induced proliferation of murine B9 hybridoma was enhanced by recombinant soluble IL-6 receptor, whereas the proliferation was inhibited by recombinant soluble gp130. These results indicate that soluble gp130 may function as a natural inhibitor of the IL-6 actions in inflammatory bowel disease.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Little is known, however, about the role of sgp130 in human diseases, including inflammatory conditions of the gastrointestinal system. One study has reported on the sgp130 levels in sera and pleural effusions from patients with metastatic carcinoma, non-Hodgkin's lymphoma, tuberculosis and cardiac failure [27].…”

Section: Introductionmentioning

confidence: 99%

A form of circulating interleukin-6 receptor component soluble gp130 as a potential interleukin-6 inhibitor in inflammatory bowel disease

Mitsuyama

Tomiyasu

Suzuki

et al. 2005

Clinical and Experimental Immunology

View full text Add to dashboard Cite

show abstract

“…Increased sIL‐6R levels in the peripheral blood have been demonstrated in various human diseases. 20–23 Recently, Mitsuyama et al demonstrated that serum sIL‐6R concentrations were raised in patients with active IBD. 24 However, little is known about intestinal sIL‐6R levels in patients with IBD and what cell types are involved in sIL‐6R secretion in the intestinal mucosal lesions of IBD.…”

Section: Introductionmentioning

confidence: 99%

Interleukin-6 and soluble interleukin-6 receptor in the colonic mucosa of inflammatory bowel disease

Hosokawa¹,

Kusugami²,

Ina³

et al. 1999

J Gastroenterol Hepatol

106

View full text Add to dashboard Cite

show abstract

“…From each patient, depending on body weight, we collected 0.1-1.0 mL of peripheral blood at up to 10 different time points. We also obtained postoperative drainage fluids from the pericardium or the pleura from five of the patients as high IL-6 concentration samples (7 ). A total of 187 samples were collected and centrifuged at 2500g for 10 min; the supernatants were collected and stored in aliquots at Ϫ80°C until analysis.…”

mentioning

confidence: 99%

Cytometric Bead Array to Measure Six Cytokines in Twenty-Five Microliters of Serum

et al. 2003

View full text Add to dashboard Cite

Infections and sepsis are among the most common reasons for neonatal morbidity and mortality. Early diagnosis is difficult because clinical presentation is highly variable and signs are often subtle and common to a variety of conditions. Among the proposed early indicators of infection and sepsis are serum concentrations of interleukin (IL)-6, IL-8, and IL-10. It is believed that IL-8 is a sensitive indicator of infection and that high concentrations of IL-6 and IL-10 are indicators of sepsis and predictors of mortality (1-3 ). The concentrations of each of these cytokines in serum vary by several orders of magnitude (1-3 ). Literature-reported cutoff values for IL-8 are Ͼ70 ng/L (2 ) or Ͼ18 ng/L (1 ) for infection, and values Ͼ10 000 ng/L have been reported (1 ). IL-6 Ͼ175 ng/L is predictive of sepsis, and values Ͼ747 ng/L are predictive for pneumonia (3 ). IL-6 is also believed to be predictive of necrotizing enterocolitis (3 ). IL-10 Ͼ420 ng/L correlates with neonatal death (3 ).The ELISAs commonly used for cytokine detection require 50 -100 L of serum (ϳ100 -200 L of peripheral blood in the neonate) per cytokine. To determine the stage of an infection, measurement of several cytokines at multiple time points can be of importance (3 ). Combining pro-and antiinflammatory cytokines in a single assay yields an overall view on the patient's inflammatory status; may allow differentiation among infection, sepsis, and enterocolitis; and thus may improve diagnostic accuracy. In neonates, however, particularly preterm neonates, such combined measurements are often hampered by lack of sufficient obtainable blood (1 ). Furthermore, although the ELISAs are adequate for measuring these cytokines, they often require multiple dilutions to cover a wide concentration range because their dynamic range is only ϳ2-3 logs.Recently, fluorescent bead array assays, such as the Cytometric Bead Array TM (CBA; BD Biosciences, San Jose, CA) (4 ), that involve measurement by flow cytometry have become available, and they have widened the assay dynamic range greatly (4,5 ). This in turn improved efficiency by decreasing the required number of dilutions. These assays are multiplexed such that numerous substances are measured simultaneously in a single well. The CBA assay consists of a mixture of six types of beads uniform in size but containing different fluorescence intensities of a red-emitting dye. A different capture antibody (Ab) against one of six cytokines is covalently coupled to each type of bead. Cytokines bound to these Abs are detected by use of Abs labeled with phycoerythrin. The fluorescence intensity measured with phycoerythrin is proportional to the cytokine concentration in the sample and is quantified from a calibration curve. The wider dynamic range is attributable to the use of florescence detection, which has a range of 4 -5 logs, and the highly efficient capturing capability of the Ab-linked particles (4 ). Particles in suspension are much more efficient than the static surface of ELISA well bottoms in capturing antig...

show abstract

IL-6 and soluble IL-6 receptors (sIL-6R and sgp130) in human pleural effusions: massive IL-6 production independently of underlying diseases

Cited by 19 publications

References 28 publications

A form of circulating interleukin-6 receptor component soluble gp130 as a potential interleukin-6 inhibitor in inflammatory bowel disease

A form of circulating interleukin-6 receptor component soluble gp130 as a potential interleukin-6 inhibitor in inflammatory bowel disease

Interleukin-6 and soluble interleukin-6 receptor in the colonic mucosa of inflammatory bowel disease

Cytometric Bead Array to Measure Six Cytokines in Twenty-Five Microliters of Serum

Contact Info

Product

Resources

About